AngioDynamics, Inc. (ANGO)
| Market Cap | 650.99M +75.5% |
| Revenue (ttm) | 320.17M +9.5% |
| Net Income | -36.74M |
| EPS | -0.88 |
| Shares Out | 41.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,066 |
| Open | 15.85 |
| Previous Close | 15.82 |
| Day's Range | 15.60 - 15.85 |
| 52-Week Range | 8.94 - 16.29 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+26.98%) |
| Earnings Date | Oct 1, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration dev... [Read more]
Financial Performance
In fiscal year 2026, AngioDynamics's revenue was $320.17 million, an increase of 9.46% compared to the previous year's $292.50 million. Losses were -$36.74 million, 8.09% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $20.0, which is an increase of 26.98% from the latest price.
News
AngioDynamics Transcript: Canaccord Genuity's 46th Annual Growth Conference
MedTech now drives nearly half of revenue, with sustained double-digit growth expected to continue as the business shifts away from legacy devices. Auryon, mechanical thrombectomy, and NanoKnife platforms are expanding into new markets, supported by clinical trials and reimbursement wins. Margin expansion, positive cash flow, and a CEO transition are key themes for FY 2027.
AngioDynamics Slides: Canaccord Genuity's 46th Annual Growth Conference
AngioDynamics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
3 Small-Cap Stocks Analysts Expect to Rally Big
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and 40%+ Upside, According to Analysts
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics price target raised to $19 from $16 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on AngioDynamics (ANGO) to $19 from $16 and keeps a Buy rating on the shares. The company reported a sales…
AngioDynamics price target raised to $20 from $16 at Canaccord
Canaccord raised the firm’s price target on AngioDynamics (ANGO) to $20 from $16 and keeps a Buy rating on the shares. The firm said AngioDynamics closed out FY26 with a…
AngioDynamics Earnings Call Transcript: Q4 2026
Revenue grew 9.4% to $320.2M in fiscal 2026, led by 18.4% Med Tech growth and margin expansion despite tariffs. Guidance for 2027 projects 5%-6.5% revenue growth, continued Med Tech momentum, and stable profitability, supported by strong cash flow and a debt-free balance sheet.
AngioDynamics Earnings release: Q4 2026
AngioDynamics released its Q4 2026 earnings on July 14, 2026, summarizing the period's financial results.
AngioDynamics Slides: Q4 2026
AngioDynamics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 14, 2026.
AngioDynamics Annual report: Q4 2026
AngioDynamics has published its Q4 2026 annual report on July 14, 2026.
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics receives FDA IDE approval for RELIEF feasibility study
AngioDynamics (ANGO) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s Investigational Device Exemption, IDE, application to initiate the RELIEF study. RELIEF is a ...
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has transformed to focus on high-growth cardiovascular and oncology markets, with innovative products like Auryon and NanoKnife driving double-digit growth and market share gains. Strong clinical results, favorable reimbursement, and a robust pipeline support continued expansion.
AngioDynamics Slides: FY 2026
AngioDynamics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics announces two-year PRESERVE trial data
AngioDynamics (ANGO) announced two-year results from the PRESERVE pivotal trial demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of...
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its portfolio, focusing on high-growth MedTech segments and innovative devices for cardiovascular and oncology markets. Strong financials, ongoing product innovation, and market expansion position it for sustained growth and margin improvement.
AngioDynamics initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of AngioDynamics (ANGO) with a Buy rating and $16 price target The firm sees an improved growth profile for the company due to its pivot to…
AngioDynamics price target lowered to $16 from $18 at Canaccord
Canaccord lowered the firm’s price target on AngioDynamics (ANGO) to $16 from $18 and keeps a Buy rating on the shares. The firm said they delivered a good FQ3 with…